Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05512104 | Clinical Characters and Outcome of Acute Myeloid Leukemia Patients on Correlation to CD200 and CD56 Expression | unknown | — | 51 | Assiut UniversityOTHER | 0 | Aug 23, 2022 | clinicaltrials |
| NCT05509335 | Ultrasound Assessment On Effectiveness of Cricoid Pressure In Paediatric Population | unknown | — | 90 | University of MalayaOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT05509374 | Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone(KMM2002) | unknown | Phase 2 | 33 | Samsung Medical CenterOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT05509530 | Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM) | unknown | Phase 2 | 30 | Xuzhou Medical UniversityOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT05498636 | SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression | unknown | Phase 1 / Phase 2 | 67 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT05504603 | Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma | unknown | Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT05473325 | Benchtop NMR Spectroscopy for Assessment of Clinical Human Pathologies (BRANCH-P STUDY)(BRANCH-P) | unknown | — | 2,000 | Willows HealthOTHER | 1 | Aug 15, 2022 | clinicaltrials |
| NCT05497102 | Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT(KMM1911) | unknown | Phase 2 | 58 | Samsung Medical CenterOTHER | 1 | Aug 12, 2022 | clinicaltrials |
| NCT05335226 | Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia | unknown | N/A | 116 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT05495100 | A Single-arm, Multicenter, Prospective Clinical Study of Mitoxantrone Liposome Combined With Chidamide and Azacitidine in the Treatment of Relapsed and Refractory Peripheral T-cell Lymphoma | unknown | Phase 2 | 45 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT05495620 | Long-term KRd in Relapsed and/or Refractory Multiple Myeloma | unknown | — | 300 | Dong-A University HospitalOTHER | 0 | Aug 10, 2022 | clinicaltrials |
| NCT01357733 | Interim FDG PET/CT in Diffuse Large B Cell Lymphoma (DLBCL) Patients | unknown | N/A | 53 | The Catholic University of KoreaOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT04226937 | DLBCL Interim Response Evaluation for Customised Therapy(DIRECT) | unknown | — | 150 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT05489276 | Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological Tumors | unknown | Phase 1 | 180 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 5, 2022 | clinicaltrials |
| NCT01374412 | Investigation of Bone Defects and Microcirculation With Computed Tomography and Magnetic Resonance Imaging | unknown | — | 144 | German Cancer Research CenterOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT02678299 | Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study | unknown | Phase 1 / Phase 2 | 60 | University of AarhusOTHER | 5 | Aug 4, 2022 | clinicaltrials |
| NCT05488132 | Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML) | unknown | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT03173612 | The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia | unknown | N/A | 132 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT04935580 | Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients | unknown | Phase 1 / Phase 2 | 20 | Shanghai Changzheng HospitalOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT05117814 | Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System Lymphoma | unknown | N/A | 20 | Peking University People's HospitalOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT05486013 | Zanubrutinib in the Treatment of Recurrent Refractory Mantle Cell Lymphoma | unknown | — | 30 | Peking University Third HospitalOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT03226301 | A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations | unknown | Phase 2 | 230 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 6 | Aug 2, 2022 | clinicaltrials |
| NCT03672084 | Allo-HSCT as First-line Consolidation in High-risk PTCL | unknown | — | 50 | Peking University People's HospitalOTHER | 1 | Aug 2, 2022 | clinicaltrials |
| NCT05013372 | CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma | unknown | Early Phase 1 | 12 | Peking University People's HospitalOTHER | 0 | Aug 2, 2022 | clinicaltrials |
| NCT05355675 | The Association of Microbiota Composition With cGVHD After Allo-HSCT | unknown | — | 300 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 2, 2022 | clinicaltrials |
| NCT05311943 | Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs. | unknown | Phase 3 | 40 | Shenzhen Second People's HospitalOTHER | 1 | Jul 29, 2022 | clinicaltrials |
| NCT05480501 | Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia | unknown | Early Phase 1 | 9 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
| NCT05477667 | Study of Let-7a and miRNA-124 in Cases of Non-Hodgkin's Lymphoma and Acute Leukemia | unknown | N/A | 100 | Sohag UniversityOTHER | 1 | Jul 28, 2022 | clinicaltrials |
| NCT05478343 | Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma | unknown | Early Phase 1 | 10 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Jul 28, 2022 | clinicaltrials |
| NCT04155411 | Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP | unknown | Phase 4 | 65 | Shenzhen Second People's HospitalOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT03373656 | Vaccination for Children of H&O and Their Parents | unknown | N/A | 300 | Children's Cancer Group, ChinaNETWORK | 1 | Jul 26, 2022 | clinicaltrials |
| NCT05412329 | Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma | unknown | Phase 1 | 9 | Shanghai Changzheng HospitalOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT05466318 | ChiCGB vs BEAM in High-risk or R/R Lymphomas | unknown | Phase 3 | 306 | Sichuan UniversityOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT05473221 | Evaluate the Safety and Efficacy of CD33 CAR-T in Patients With R/R AML | unknown | Phase 1 | 20 | Zhejiang UniversityOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT03736616 | Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL | unknown | Phase 2 | 47 | Swedish Medical CenterOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT04271215 | Overweight and Obesity as Prognostic Factors for Survival in Children With Acute Lymphoblastic Leukemia | unknown | — | 1,200 | Coordinación de Investigación en Salud, MexicoOTHER_GOV | 1 | Jul 20, 2022 | clinicaltrials |
| NCT05467202 | Evaluate the Safety and Efficacy of CLL1 CAR-T in Patients With R/R AML | unknown | Phase 1 | 20 | Zhejiang UniversityOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT05467254 | Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With R/R AML | unknown | Phase 1 | 20 | Zhejiang UniversityOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT05463640 | Evaluate the Safety and Efficacy of ADGRE2 CAR-T in Patients With R/R AML | unknown | Phase 1 | 20 | Zhejiang UniversityOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT05458180 | CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma | unknown | Phase 1 | 18 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 14, 2022 | clinicaltrials |
| NCT05455866 | Central Venous Catheter-related Complications in Patients Under Anticancer Treatment(KTcCHO) | unknown | — | 100 | Centre Hospitalier Alpes LemanOTHER | 0 | Jul 13, 2022 | clinicaltrials |
| NCT05449886 | Prone Fluid Responsiveness in Children | unknown | N/A | 40 | Seoul National University HospitalOTHER | 1 | Jul 12, 2022 | clinicaltrials |
| NCT05453669 | Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHL | unknown | Phase 1 | 12 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 12, 2022 | clinicaltrials |
| NCT05444322 | A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma | unknown | Early Phase 1 | 18 | He HuangOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT05381506 | Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma(O-Gemox) | unknown | Phase 2 | 77 | Sun Yat-sen UniversityOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT05448404 | A Head-to-head Comparative Study of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT Imaging in Multiple Myeloma | unknown | N/A | 30 | First Hospital of China Medical UniversityOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT04460508 | Mecapegfilgrastim(PEG-G-CSF) for Prophylaxis of Chemotherapy-induced Neutropenia in Patients With Lymphoma | unknown | Phase 2 | 170 | The First Hospital of Jilin UniversityOTHER | 1 | Jul 7, 2022 | clinicaltrials |
| NCT04845139 | A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma | unknown | N/A | 1 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 7, 2022 | clinicaltrials |
| NCT05446688 | A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma | unknown | Phase 2 | 40 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 0 | Jul 7, 2022 | clinicaltrials |
| NCT03493217 | A Study to Evaluate ICP-022 in Patients With CLL/ SLL | unknown | Phase 1 / Phase 2 | 100 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jul 6, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Aug 23, 2022source: clinicaltrials